Federico Cappuzzo
Guide to Targeted Therapies: Treatment Resistance in Lung Cancer (eBook, PDF)
53,49 €
inkl. MwSt.
Sofort per Download lieferbar
Federico Cappuzzo
Guide to Targeted Therapies: Treatment Resistance in Lung Cancer (eBook, PDF)
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
![](https://bilder.buecher.de/images/aktion/tolino/tolino-select-logo.png)
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
![](https://bilder.buecher.de/images/aktion/tolino/tolino-select-logo.png)
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 0.86MB
- Upload möglich
Andere Kunden interessierten sich auch für
- Lung Cancer (eBook, PDF)171,19 €
- Lung Cancer (eBook, PDF)139,09 €
- Lung Cancer Screening (eBook, PDF)53,49 €
- Treatment Resistance in Psychiatry (eBook, PDF)160,49 €
- Management of Lung Cancer in Older People (eBook, PDF)106,99 €
- Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies (eBook, PDF)106,99 €
- Iago Dillion Lima CavalcantiAdvances in Cancer Treatment (eBook, PDF)80,24 €
-
-
-
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.
Produktdetails
- Produktdetails
- Verlag: Springer International Publishing
- Erscheinungstermin: 15. Oktober 2015
- Englisch
- ISBN-13: 9783319207414
- Artikelnr.: 43956768
- Verlag: Springer International Publishing
- Erscheinungstermin: 15. Oktober 2015
- Englisch
- ISBN-13: 9783319207414
- Artikelnr.: 43956768
Federico Cappuzzo, MD, has been the Director of the medical oncology department at the Istituto Toscano Tumori-Ospedale Civile-Livorno in Livorno, Italy since January 2010. In November 1992, he graduated, summa cum laude, in medicine and surgery at the Palermo University. In November 1996, he gained a degree, summa cum laude, in medical oncology at Milan University, followed by the European Society for Medical Oncology (ESMO) certification in medical oncology in 1997. From 1997 to 1999, he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). He then was an attending physician at the thoracic oncology unit at the Medical University of South Carolina in Charleston from April 2000 to September 2000. For six years, from November 2000 to 2006, he was an assistant professor at Ospedale Bellaria in Bologna. From November 2006 to January 2010, Dr Cappuzzo was an assistant professor in medical oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milan), and from January 2004 to November 2004 he was a visiting associate professor in medical oncology at University of Colorado in Denver. Dr Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), ESMO, American Society Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASCL), and since 2006 has been a member of the editorial board of Lung Cancer. In 2006 and 2009, he received research grants from the Italian Association for Cancer Research (AIRC) on targeted therapies in lung cancer and is the author of more than 150
papers in peer-review journals, mainly in translational research in lung cancer.
has been the Director of the medical oncology department at the Istituto Toscano Tumori-Ospedale Civile-Livorno in Livorno, Italy since January 2010. In November 1992, he graduated, summa cum laude, in medicine and surgery at the Palermo University. In November 1996, he gained a degree, summa cum laude, in medical oncology at Milan University, followed by the European Society for Medical Oncology (ESMO) certification in medical oncology in 1997. From 1997 to 1999, he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). He then was an attending physician at the thoracic oncology unit at the Medical University of South Carolina in Charleston from April 2000 to September 2000. For six years, from November 2000 to 2006, he was an assistant professor at Ospedale Bellaria in Bologna. From November 2006 to January 2010, Dr Cappuzzo was an assistant professor in medical oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milan), and from January 2004 to November 2004 he was a visiting associate professor in medical oncology at University of Colorado in Denver. Dr Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), ESMO, American Society Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASCL), and since 2006 has been a member of the editorial board of Lung Cancer. In 2006 and 2009, he received research grants from the Italian Association for Cancer Research (AIRC) on targeted therapies in lung cancer and is the author of more than 150 papers in peer-review journals, mainly in translational research in lung cancer.
papers in peer-review journals, mainly in translational research in lung cancer.
has been the Director of the medical oncology department at the Istituto Toscano Tumori-Ospedale Civile-Livorno in Livorno, Italy since January 2010. In November 1992, he graduated, summa cum laude, in medicine and surgery at the Palermo University. In November 1996, he gained a degree, summa cum laude, in medical oncology at Milan University, followed by the European Society for Medical Oncology (ESMO) certification in medical oncology in 1997. From 1997 to 1999, he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). He then was an attending physician at the thoracic oncology unit at the Medical University of South Carolina in Charleston from April 2000 to September 2000. For six years, from November 2000 to 2006, he was an assistant professor at Ospedale Bellaria in Bologna. From November 2006 to January 2010, Dr Cappuzzo was an assistant professor in medical oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milan), and from January 2004 to November 2004 he was a visiting associate professor in medical oncology at University of Colorado in Denver. Dr Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), ESMO, American Society Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASCL), and since 2006 has been a member of the editorial board of Lung Cancer. In 2006 and 2009, he received research grants from the Italian Association for Cancer Research (AIRC) on targeted therapies in lung cancer and is the author of more than 150 papers in peer-review journals, mainly in translational research in lung cancer.
1 Introduction
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion
1 Introduction
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion
1 Introduction
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion
1 Introduction
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion
References
2 Therapy options for advanced NSCLC
First-line chemotherapy and anti-angiogenic agents
First-line EGFR tyrosine kinase inhibitors
ALK inhibitors
References
3 Resistance to EGFR TKIs
Primary resistance to EGFR-TKIs
Acquired resistance to EGFR-TKIs
References
4 Overcoming EGFR-TKI resistance
Overcoming resistance with EGFR-targeted agents
Overcoming EGFR-TKI resistance by targeting alternate pathways
References
5 Resistance to crizotinib and therapeutic options
Target-dependent mechanisms
Non-target-dependent mechanisms
Crizotinib beyond progression
Second-generation ALK inhibitors
Other agents
References
6 Resistance to anti-angiogenic drugs and therapeutic options
References
7 Conclusion